Stock

Bicara Therapeutics Inc. BCAX

$27.19-1.88%

All stocks Create account to unlock

Overview

BCAX market data

Price History

BCAX price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for BCAX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

5 captured

Bicara Therapeutics' Ficerafusp Alfa Plus Pembrolizumab Shows 31% Estimated 3-Year Overall Survival And Durable Responses In First-Line HPV-Negative Head And Neck Cancer Phase 1b Study · May 21, 2026, 9:15 PM

8-K filing — Bicara Therapeutics Inc. (BCAX) · May 21, 2026, 9:04 PM

Bicara Therapeutics shares are trading lower. The company reported worse-than-expected Q1 EPS results. · May 11, 2026, 12:40 PM

Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate · May 11, 2026, 11:30 AM

Earnings Scheduled For May 11, 2026 · May 11, 2026, 11:11 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock